课题基金 / 基金详情

Study on Clinical Application of Chinese Herbal Medicine as A Biological Response Modifier

Study on Clinical Application of Chinese Herbal Medicine as A Biological Response Modifier
中草药作为生物反应调节剂的临床应用研究
批准号:
01870049
负责人:
SUGAHARA Tsutomu
金额:
$1.92万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Developmental Scientific Research (B).
财政年份:
1989
资助国家:
日本
项目状态:
已结题
起止时间:
1989 至 1990

项目摘要

项目成果

SUGAHARA Tsutomu的其他基金

相似基金

相关文献

中文摘要
翻译
本论文对中草药MCX-912进行了沿着临床试验,并结合分析化学、生物化学、细胞生物学、肿瘤学和药理学等方面的研究成果进行了表征。以下是结果总结。(1)MCX-912含有0.8%的K,Fe,Zn,Cu(总量:0.9%),42.0%的蛋白质和7.2%的糖。(2)虽然MCX-912对EMT 6单细胞的细胞杀伤活性很小,但MCX-912显著增强了X照射细胞的致死性损伤。(3)荷SCC VII瘤小鼠单次X线照射后,每天皮下注射MCX-912,放射效应增强1.4倍。使用MCX-912与低氧细胞放射增敏剂和/或热疗可以实现进一步增强。(4)MCX-912促进了芬顿试剂对过氧化氢的分解。(6)MCX-912对S180实体瘤具有抗肿瘤作用。(7)每天向MM 46荷瘤小鼠施用MCX-912不产生抗肿瘤作用。然而,脾细胞的数量增加,从而腹膜内的MM 46细胞越来越失活。(8)对患者施用MCX-912后,淋巴细胞亚群中的细胞毒性T细胞数量增加。(9)MCX-912可改善患者的体力状态,这是由于患者食欲增加,剧烈疼痛减轻或消失。
英文摘要
Clinical assay of Chinese herbal medicine MCX-912, which was extract from earthworm, has been carried out along with characterization based on analytical chemistry, biochemistry, cell biology, oncology, and pharmacology. The followings are the summary of results.(1) MCX-912 contains 0.8% K, Fe, Zn, Cu (total amount : 0.9%), 42.0% proteins, and 7.2% sugars.(2) Although cell killing activity of MCX-912 on EMT6 single cells is small, the lethal damage of X-irradiated cells is considerably enhanced by MCX-912.(3) Administration of MCX-912 everyday to SCC VII tumor bearing mice in their thinghs after single X-irradiation results in 1.4 times enhancement of radiation effect. Further enhancement can be achieved using MCX-912 together with hypoxiccell radiosensitizers and/or hyperthermia.(4) Decomposition of hydrogen peroxide by the Fenton's reagent is accelerated by MCX-912.(6) MCX-912 shows an antitumor effect on S180 solid tumors.(7) Administration of MCX-912 everyday to MM46 tumor bearing mice gives rise to no antitumor effect. However, number of spleen cells increases and thereby intraperitoneal MM46 cells are increasingly inactivated.(8) Number of cytotoxic T-cells in the lymphocyte subsets increases on administration of MCX-912 to patients.(9) Performance status is improved by MCX-912, due to the increase of appetite and the decrease or disappearance of sever pain for patients.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
TSUCHIYA,Takehiko: "Local RFーWave Hyperthermia(8MHz)Combined with Radiotherapy in Advanced Lung Cancer" Hyperthermic Oncology. 1. 427-428 (1989)
TSUCHIYA, Takehiko:“局部射频波热疗 (8MHz) 与放射治疗相结合治疗晚期肺癌”热肿瘤学。 1. 427-428 (1989)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
SUGAHARA, T: "Heat Schock-Protein Induced in Transformed Cells are Different from Those Induced in Normal Cells" Hyperthermic Oncology. 1. 54-55 (1989)
SUGAHARA, T:“转化细胞中诱导的热休克蛋白与正常细胞中诱导的热休克蛋白不同”热肿瘤学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tsutomu Sugahara: "Cellular Sensitivity to Environmental Stresses are Correlated with Rates of Recovery of Protein Synthesis" Hyperthermic Oncology. 1. 274-276 (1989)
Tsutomu Sugahara:“细胞对环境压力的敏感性与蛋白质合成的恢复率相关”热肿瘤学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 21 条
    Exploitation of high functional chiral building blocks by meso-asymmetrization using Ru^<II> catalyst.
    • 批准号:
      10671982
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.05万
    • 财政年份:
      1998
    • 负责人:
      SUGAHARA Tsutomu
    • 依托单位:
    国内基金
    海外基金
    Cellular & Molecular Immunology
    • 批准号:
      30824806
    • 项目类别:
      专项基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2008
    • 负责人:
      魏海明
    • 依托单位: